SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CYCN

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)

US · Delayed Price · Currency is USD
Also listed: KRSAHealthcare · Biotechnology
$23.52+$0.00 (+0.00%)
 
Market cap
$15.7M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 18, 2019
Market Cap$15.73M+33.3%
Revenue (ttm)$1.02M-64.1%
Net Income-$52.16M-2271.8%
EPS-$77.99-151.3%
Shares Out668.76K
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume435,847
Open$3.72
Previous Close$23.52
Day's Range$2.82 - $23.52
52-Week Range$2.82 - $59.36
Beta1.75
AnalystsBuy
Price Targetn/a
Earnings Daten/a
No price history available.

About CYCN

Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement. Concurrently, CY6463 is undergoing Phase 1 trials for treating schizophrenia in adult populations. The company's research portfolio also features other promising candidates: Praliciguat, an orally administered systemic sGC stimulator, is in Phase II studies targeting resistant hypertension and diabetic nephropathy. Olinciguat, another sGC stimulator designed for oral intake with a vascular focus, is progressing through Phase II trials for sickle cell disease. Moreover, CY3018 is under development to address a range of CNS ailments. Cyclerion holds a licensing agreement with Akebia Therapeutics, Inc., covering the entire lifecycle from development and manufacturing to medical affairs and commercialization for certain pharmaceutical compounds and related products. The company was founded in 2018 and has its principal place of business in Cambridge, Massachusetts.

Address
245 First Street, Cambridge, MA, 02142, US
Market Cap
16 million
Employees
1
Industrial Classification
Biotechnology
Financial Health Score
Fair
From CYCN’s reported statements · Q3 2026 (trailing 12 months)
1 Day
+0.00%
5 Days
-26.01%
1 Month
+0.00%
6 Months
+16.26%
1 Year
+33.33%

$CYCN stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CYCN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CYCN's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CYCN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New CYCN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CYCN from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CYCN

ONEQFidelity Nasdaq Composite Index ETF$110.85K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CYCN’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.